Clinical Scenario 1 With Bispecifics in R/R MM

Clinical Scenario 1 with Bispecifics in Relapsed/Refractory Multiple Myeloma (R/R MM)

This scientific case presents a person aged 64 years with high-risk a number of myeloma that includes 17p deletion and t(4;14) translocation who has obtained 6 prior strains of remedy, together with lenalidomide, carfilzomib, daratumumab, selinexor, and belantamab. After 4 cycles of therapy, he initiated weekly dosing that was subsequently diminished to each 1.5 weeks, reaching a stringent full response and sustaining minimal residual illness negativity for 11 months earlier than experiencing illness development. The development manifested as rising mild chains, new lytic lesions, and 50% plasma cells within the bone marrow, with circulate cytometry demonstrating decreased BCMA floor expression in contrast with baseline, suggesting antigen loss as a possible resistance mechanism.

This case highlights the difficult decision-making course of when sufferers progress after BCMA-directed remedy with proof of antigen downregulation. The decreased BCMA expression means that retreatment with one other BCMA-targeted bispecific could have restricted efficacy, making goal switching to GPRC5D-directed remedy a logical consideration. However, the affected person’s closely pretreated standing and high-risk cytogenetics add complexity to therapy choice. Options embody pursuing compassionate use entry to investigational brokers, enrolling in scientific trials, or contemplating GPRC5D-targeted bispecific remedy regardless of considerations about sequential bispecific use.

The MonumenTAL-1 research included a cohort of sufferers with prior T-cell–redirecting therapies, which offers some reassurance in regards to the feasibility of sequential bispecific use. However, these knowledge are confounded by the heterogeneity of prior therapies and affected person populations. The case emphasizes the necessity for added knowledge on sequential bispecific methods and highlights the significance of mixture approaches or “sandwich” therapies between bispecific remedies to probably restore T-cell perform. Clinical trial enrollment stays an necessary consideration for closely pretreated sufferers with proof of resistance mechanisms, though sensible challenges, together with washout durations and eligibility standards, could restrict entry to investigational therapies.